Your observations are off the chart of reality in my
Your observations are off the chart of reality in my opinion. We are not a candidate for a buy out.
As for other observations that I heard. I just finished the call. I am disappointed that Mahboob is no longer with us. I knew it was a big step backwards for him to come to little ol’ Cytodyn when he came and I had hoped that he would stay long enough to possibly replace Nader as CEO. My assumption is he was head hunted by another Pharma and the offer was too good to pass up. He has I am sure a big networking group who knows what his accomplishments are. I wish him good luck. We will miss his experience but will get bye without him. Nobody is irreplaceable.
It looks like they have it covered with another company coming in to help finish the BLA and they had Amerex working with Mahboob and his 2-3 people he had come to Cytodyn with him. ( Wonder if they went too?) Either way. Amerex probably benefitted from Mahboob enough to complete the formatting of the BLA. It may be the only needed items left are the completion of the receptor occupancy testing from the two companies they have hired to help that. Maybe Mahboob left because his job was complete on why he was hired?
Either way it looks like the BLA will probably be held to a RO testing completion as the delay or maybe still on schedule for late June or early July like we were told before. Either way we move on.
As for Covid it has two different takes for me. One is... we might get an EUA but it will take the extention of the CD-12 trial to 70 people like we were told it would take to achieve a p value in mortality
to get a updated p value. Did you hear that stat of 17.6% mortality in the 55 people in the extention? That seems to be on the table still for EUA. If not then another trial it will take. That was 3 different trial options thrown out there for another trial. If we had revenue we could do all 3. We sure do need some revenue.
The second most likely scenario for quick revenue and possible EUA is another country will be our first EUA. Time will tell on this. It seems closer every PR.
As for cancer having a BTD pre-meeting in the near future. I am happy to hear that but it doesn’t sound like it will happen soon and if it does. That would be a huge deal. Look forward to hearing about that possibility.
It was nice to hear the updates on LH and Dr. Recknor was a pleasure to hear speak to symptoms and how his personal experience was overcome with help from Leronlimab. His outlook for the LH trial was encouraging also. This will be the biggest treating group in Covid for us so hearing positive things are great.
Nash was still ongoing and not an issue with abundant information. Time will tell.
Over all I would say Nader was a little guarded and rightly so with all the armchair quarterbacking questions he was asked about what if...
We didn’t get any great news but we are not dropping the ball in any area and all is stable and it appears they have many many coals in the fire all over the world in seeking sales. This will happen and I believe soon. The Devastation in many countries shows all the need. Part of the puzzle they all seek is a critical ICU drug that will relieve some pressure on the ICU’s in all countries. That’s us...
9
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Actinium Pharmaceuticals Steps into the Spotlight Alright, folks, here we have Actinium Pharmaceuticals, Inc. gearing up to make some noise at the H.C. Wainwright 28th Annual Global Investment Conference. This isn't just any roadshow—it's a chance to showcase the kind of pioneering work they're doing in targeted radiotherapies. With Sandesh Seth, the Chairman, taking...
Continue Reading
Why Laughing Gas is a Game-Changer in Pediatric Dentistry You ever seen a kid freeze up like a deer in headlights at the dentist's office? I'm telling you, it's not just the sweet tooth nightmare but often the fear of that cold, intimidating chair. But let's talk about a game-changer: laughing gas or, known in the trade as nitrous oxide. Keeping Anxiety at Bay: The Role...
Continue Reading
Breathing New Life into Clinical Trials Alright, folks, listen up. We've got a fresh collaboration cooking that could shake things up in the clinical trial sector. Signant Health, a heavyweight in clinical trial solutions, has teamed up with Lothar Medical, and they’ve hitched their wagons to launch something rather intriguing: the ALDS PRO pulmonary function tech. Let...
Continue Reading
Pushing Forward Yet Stumbling on the Details We've got a fresh scoop from the AI Leaders Council: They just rolled out their 2026 Corporate AI Talent Study. What's the big fuss? Well, they're tracking how companies are cozying up to artificial intelligence. Let's just say it's a mixed bag this time around. While almost everyone jumped on the AI bandwagon, only a scant 3%...
Continue Reading
Why Virterion Stands Out in 2026 VPS Landscape For anyone knee-deep in the hosting game, you know the market's got more players than a late-night poker round. Virterion, though—that's a name carving out a noticeable niche, and for solid reasons. In 2026, the backdrop's not just speed, it’s about matching technology and support with what ambitious developers need. VPS...
Continue Reading
Cooking Up High Margins and Rapid Growth You don’t stumble on opportunities like this every day. A foodservice company out there is posting some mouth-watering numbers, and it’s shaking up the M&A scene. This one’s got patents holding up its brand like a culinary force field, and it’s now on the auction block for a cool $1.6 million. And the numbers? Well, they...
Continue Reading
Shifting Gears at the Checkout Counter Let's face it, we've all been there: you click, you pay, and then you wait. But what happens next is where brands often drop the ball. Sure, e-commerce has been all about getting us to trust the 'buy' button. That's where folks like XCOTTON are stepping up to the plate, giving us something else to consider. They were loud and clear...
Continue Reading
Overnight Sensation or Future Staple? I wonder if Dreame's top brass woke up sweating or smiling after their big reveal at IFA 2026. A buffet of over 100 products across 16 categories is no small feat, especially when you're banking on technologies developed over nine years. But let's cut through the noise—does this showcase promise innovation or just smoke and mirrors?...
Continue Reading
Wrapping Up a Wild Ride in the Investment Arena Markets are a fickle friend, and today we've got Inturai Ventures calling it a day on their latest cash grab. They've locked the final tranche of their private placement, pulling in an aggregate $963,713.70. Feels like they're counting pennies in this venture, but every cent counts when your aim is to shake up industries...
Continue Reading
Legal Storm Brewing with AEVEX's IPO Disclosures Whatever happened to straightforward honesty in business? AEVEX Corp. (NYSE: AVEX) might have forgotten that chapter judging by fresh allegations in their midst. Investors who bought AVEX Class A common stock between April 17 and June 4, 2026, have been hit with a curveball: a looming class action lawsuit for securities...
Continue Reading
ing Brands Faces Legal Probe; Fiduciary Duties Questioned">
Continue Reading